A360
Key Takeaways✦ Atlas AI
01
3.1 million eye drop bottles recalled.
02
Sterility concerns prompted FDA action.
03
Recall is Class II, low serious risk.
Atlas AI
More than 3.1 million bottles of over-the-counter eye drops have been recalled after manufacturer K.C. Pharmaceuticals flagged potential sterility issues, according to an announcement by the Food and Drug Administration (FDA) dated March 3. The products were sold through major US retailers, including Walgreens and CVS, and the agency said consumers who purchased the affected eye drops should stop using them.
The FDA classified the action as a “Class II” recall. Under that designation, the agency said the products may lead to temporary or medically reversible adverse health consequences, while the probability of serious harm is considered remote. The FDA’s notice ties the recall to sterility concerns rather than a confirmed contamination event in the announcement.
The recall covers eight distinct brands manufactured by K.C. Pharmaceuticals. The largest single lot cited involves more than 1 million bottles of Dry Eye Relief Eye Drops. Distribution for that product included retailers such as Rite Aid, H-E-B, and Harris Teeter, according to the FDA’s announcement.
Other recalled products named by the FDA include Artificial Tears Sterile Lubricant Eye Drops, Sterile Eye Drops Original Formula, and Sterile Eye Drops Redness Lubricant. The notice said these items were sold across a mix of pharmacy chains and general merchandise stores, widening the potential consumer footprint beyond a single retailer network.
The FDA’s update also pointed to a prior episode in 2023, when a separate recall involving a different manufacturer was linked to bacterial contamination. While the current action involves K.C. Pharmaceuticals and is described as a sterility concern, the reference highlights continued attention on manufacturing controls and quality assurance for non-prescription ophthalmic products.
For retailers and suppliers, the recall creates immediate operational steps, including removing affected inventory and managing customer notifications and returns. For consumers, the agency’s guidance is straightforward: discontinue use of the recalled eye drops, reflecting the FDA’s view that adverse effects are possible even if severe outcomes are unlikely under the Class II framework.
What remains unclear from the FDA announcement is the specific mechanism behind the sterility concern, including whether it relates to production, packaging, or handling, and whether any adverse events were reported. The recall nonetheless underscores ongoing regulatory scrutiny of over-the-counter eye care products aimed at protecting consumer safety in a category that is widely used and often purchased without medical supervision.
Related Articles
About this story
Atlas360 covers Health as part of a broader effort to give international readers fast, source-checked context on global affairs. Our newsroom monitors original reporting from wire services, accredited correspondents and verified eyewitness accounts, then re-summarises the most important facts in clear, plain-language English so that you can understand both what happened and why it matters.
Every published article on Atlas360 is reviewed for accuracy, balance and timeliness before it reaches the homepage. When new information emerges — for example a correction from an official source, a casualty update, or a clarifying statement from a named spokesperson — we update the story in place and keep the original publication time so readers can track how a developing situation evolves.
If you want to keep following Health, you can browse the related coverage at the foot of this page, subscribe to the Atlas360 newsletter for a daily roundup, or open the relevant topic page where every story we have published on the subject is listed in reverse chronological order. Reader signals from the community feed also shape which threads we keep reporting on.